QC
IPXL

Quadrature Capital’s Impax Laboratories, Inc. IPXL Stock Holding History

Quadrature Capital’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-16,903
Closed -$224K – 964
2016
Q4 		$224K Buy
+16,903
New +$289K 0.01% 573

Other funds holding IPXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Quadrature Capital's IPXL Position: Q1 2017 in Review

Quadrature Capital sold out of Impax Laboratories, Inc. (IPXL) in Q1 2017, closing a stake of 16,903 shares — an estimated $224K sold.

Quadrature Capital first reported a position in IPXL in Q4 2016 and held it in 1 quarter. The position peaked at $224K in Q4 2016. 178 funds tracked by Wall St. Rank hold IPXL as of Q1 2017.

  • Quadrature Capital reported no remaining Impax Laboratories, Inc. position as of Q1 2017 after selling out during the quarter.
  • Quadrature Capital sold 16,903 Impax Laboratories, Inc. shares in Q1 2017, an estimated $224K.
  • Quadrature Capital first reported a position in Impax Laboratories, Inc. in Q4 2016 and held it in 1 quarter.
  • Quadrature Capital's Impax Laboratories, Inc. position peaked at $224K in Q4 2016.
  • 178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2017.

Based on Quadrature Capital's 13F filing for Q1 2017, filed 12 May 2017.